Bellicum Pharmaceuticals (Bellicum Pharmaceuticals) 3-Year EBITDA Growth Rate : 65.50% (As of Sep. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Bellicum Pharmaceuticals 3-Year EBITDA Growth Rate?

Bellicum Pharmaceuticals's EBITDA per Share for the three months ended in Sep. 2023 was $-0.03.

During the past 3 years, the average EBITDA Per Share Growth Rate was 65.50% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 54.70% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 26.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 11 years, the highest 3-Year average EBITDA Per Share Growth Rate of Bellicum Pharmaceuticals was 72.50% per year. The lowest was -48.00% per year. And the median was 29.10% per year.

Competitive Comparison of Bellicum Pharmaceuticals's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Bellicum Pharmaceuticals's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bellicum Pharmaceuticals's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bellicum Pharmaceuticals's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Bellicum Pharmaceuticals's 3-Year EBITDA Growth Rate falls into.

Bellicum Pharmaceuticals 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Bellicum Pharmaceuticals (OTCPK:BLCM) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Bellicum Pharmaceuticals 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Bellicum Pharmaceuticals's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Bellicum Pharmaceuticals (Bellicum Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bellicum Pharmaceuticals Inc (OTCPK:BLCM) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

BPXA:Germany

Address

3730 Kirby Drive, Suite 1200, Houston, TX, USA, 77098

Website

https://www.bellicum.com

Bellicum Pharmaceuticals Inc is a biopharmaceutical company that has discovered and developed novel, controllable cellular immunotherapies for various forms of cancer, including both hematological cancers and solid tumors. its proprietary Chemical Induction of Dimerization technology platform is designed to enable control of components of the immune system in real-time. Its product candidates are; BPX-601 an autologous GoCAR-T product candidate designed to treat solid tumors expressing prostate stem cell antigen, or PSCA, and BPX-603 an autologous dual-switch GoCAR-T product candidate designed to target solid tumors that express the human epidermal growth factor receptor 2 antigen, or HER2.

Executives

Charity Scripture	officer: Chief Development Officer	C/O BELLICUM PHARMACEUTICALS, INC., 3730 KIRBY DRIVE, STE. 1200, HOUSTON TX 77098
James M Daly	director	INCYTE CORPORATION EXPERIMENTAL STATION, RTE 141 & HENRY CLAY RD. BLDG E336, WILMINGTON DE 19880
Stephen Davis	director	ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Charles S. Grass	officer: Principal Accounting Officer	C/O BELLICUM PHARMACEUTICALS, INC., 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098
Richard A. Fair	director, officer: President and CEO	C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030
David Eric Strauss	officer: Director, Corporate Controller	2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030
Shane Ward	officer: Sr. VP and General Counsel	C/O VERSARTIS, INC., 4200 BOHANNON DR., SUITE 250, MENLO PARK CA 94025
Woodard Jr Joseph Paul	officer: SVP Clinical & Medical Affairs	C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030
Aaron E. Foster	officer: Sr VP, Head of Research	C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE 800, HOUSTON TX 77030
Rosemary Y. Williams	officer: Principal Accounting Officer	2130 W. HOLCOMBE BOULEVARD, SUITE 800, HOUSTON TX 77030
Judith V Klimovsky	director	C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030
Atabak Mokari	officer: Sr. VP and CFO	1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Jon P Stonehouse	director	2190 PARKWAY LAKE DR, BIRMINGHAM AL 35244
David M. Spencer	officer: Chief Scientific Officer	C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030
Alan A Musso	officer: CFO and Treasurer	FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139